Are there optimal alanine aminotransferase and HBV DNA thresholds for discriminating HBeAg-positive chronic infection from chronic hepatitis?

References

1. ↵
   1. Sarin S,
   2. Kumar M,
   3. Lau G,
   4. Abbas Z,
   5. Chan H,
   6. Chen C,
   7. et al.

   (2016) Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update. Hepatol Int 10:1–98.

   OpenUrlCrossRefPubMed
2. ↵
   1. Terrault NA,
   2. Bzowej NH,
   3. Chang KM,
   4. Hwang JP,
   5. Jonas MM,
   6. Murad MH

   (2016) AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63:261–283.

   OpenUrlCrossRefPubMed
3. ↵
   1. Özkan H

   (2018) Epidemiology of Chronic Hepatitis B in Turkey. Euroasian J Hepatogastroenterol 8:73–74.

   OpenUrl
4. ↵
   1. Lampertico P,
   2. Agarwal K,
   3. Berg T,
   4. Buti M,
   5. Janssen HL,
   6. Papatheodoridis G,
   7. et al.

   (2017) EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 67:370–398.

   OpenUrlCrossRefPubMed
5. ↵
   1. World Health Organization

   (2015) Guidelines for the prevention care and treatment of persons with chronic hepatitis B infection (World Health Organization, Geneva).
6. ↵
   1. Yenilmez E,
   2. Çetinkaya RA,
   3. Tural E

   (2018) Diagnostic dilemma for low viremia with significant fibrosis;is hepatitis B virus DNA threshold level a good indicator for predicting liver damage? Balkan Med J 5:326.

   OpenUrl
7. ↵
   1. Lai M,
   2. Hyatt BJ,
   3. Nasser I,
   4. Curry M,
   5. Afdhal NH

   (2007) The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 47:760–767.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   1. Tseng TC,
   2. Kao JH

   (2015) Treating immune-tolerant hepatitis B. J Viral Hepat 22:77–84.

   OpenUrl
9. ↵
   1. Andreani T,
   2. Serfaty L,
   3. Mohand D,
   4. Dernaika S,
   5. Wendum D,
   6. Chazouillères O,
   7. et al.

   (2007) Chronic hepatitis B virus carriers in the immunotolerant phase of infection:histologic findings and outcome. Clin Gastroenterol Hepatol 5:636–641.

   OpenUrlPubMed
10. ↵
    1. Vlachogiannakos J,
    2. Papatheodoridis GV,
    3. Hepatitis B

    (2018) Who and when to treat? Liver Int 38:71–78.

    OpenUrl
11. ↵
    1. Papatheodoridis GV

    (2013) Hepatitis B virus treatment:Which patients can have treatment deferred? Clinical Liver Disease 2:15–17.

    OpenUrl
12. ↵
    1. Tabak F,
    2. Yurdaydın C,
    3. Idilman R

    (2017) Diagnosis, management and treatment of hepatitis B virus infection:Turkey 2017 clinical practice guidelines. Turk J Gastroenterol 28:73–83.

    OpenUrl
13. ↵
    1. Kennedy PT,
    2. Litwin S,
    3. Dolman GE,
    4. Bertoletti A,
    5. Mason WS

    (2017) Immune tolerant chronic hepatitis B:the unrecognized risks. Viruses 9:96.

    OpenUrl
14. ↵
    1. Toy M,
    2. Onder FO,
    3. Idilman R,
    4. Kabacam G,
    5. Richardus JH,
    6. Bozdayi M,
    7. et al.

    (2012) The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. Eur J Health Econ 13:663–676.

    OpenUrlPubMed
15. ↵
    1. Arama V,
    2. Leblebicioglu H,
    3. Simon K,
    4. Zarski JP,
    5. Niederau C,
    6. Habersetzer F,
    7. et al.

    (2014) Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies. Antivir Ther 19:245–257.

    OpenUrlPubMed
16. ↵
    1. Shao J,
    2. Wei L,
    3. Wang H,
    4. Sun Y,
    5. Zhang L-F,
    6. Li J,
    7. et al.

    (2007) Relationship between hepatitis B virus DNA levels and liver histology in patients with chronic hepatitis B. World journal of gastroenterology. World J Gastroenterol 13:2104.

    OpenUrlPubMed
17. 1. Marugán RB,
    2. Garzón SG

    (2009) DNA-guided hepatitis B treatment, viral load is essential, but not sufficient. World Journal of Gastroenterology. World J Gastroenterol 15:423.

    OpenUrlPubMed
18. 1. Barut S,
    2. Gemici Ü,
    3. Güneş F,
    4. Demir O,
    5. Duygu F

    (2017) Predictors of histological indication for treatment in HBeAg negative chronic HBV infection. J Med Virol 89:1952–1957.

    OpenUrl
19. ↵
    1. Diktas H,
    2. Karacaer Z,
    3. Özturk II,
    4. Cicek H

    (2016) Comparison of relationship between histopathological, serological and biochemical parameters in patients with chronic hepatitis B infection. Postgrad Med J 92:693–696.

    OpenUrlAbstract/FREE Full Text
20. ↵
    1. Xie Q,
    2. Hu X,
    3. Zhang Y,
    4. Jiang X,
    5. Li X,
    6. Li J

    (2014) Decreasing hepatitis B viral load is associated with a risk of significant liver fibrosis in hepatitis B e antigen positive chronic hepatitis B. J Med Virol 86:1828–1837.

    OpenUrl
21. ↵
    1. Zeng DW,
    2. Zhang JM,
    3. Liu YR,
    4. Dong J,
    5. Jiang JJ,
    6. Zhu YY

    (2016) A retrospective study on the significance of liver biopsy and hepatitis B surface antigen in chronic hepatitis B infection. Medicine (Baltimore) 95:e2503.

    OpenUrl
22. ↵
    1. Kumar M,
    2. Sarin SK,
    3. Hissar S,
    4. Pande C,
    5. Sakhuja P,
    6. Sharma BC,
    7. et al.

    (2008) Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 134:1376–1384.

    OpenUrlPubMed
23. ↵
    1. Wong GLH,
    2. Wong VWS,
    3. Choi PCL,
    4. Chan AWH,
    5. Chim AML,
    6. Yiu KKL,
    7. et al.

    (2009) Clinical factors associated with liver stiffness in Hepatitis B e antigen–positive chronic hepatitis B patients. Clin Gastroenterol Hepatol 7:227–233.

    OpenUrlCrossRefPubMed
24. ↵
    1. Seto WK,
    2. Lai CL,
    3. Ip PP,
    4. Fung J,
    5. Wong DKH,
    6. Yuen JCH,
    7. et al.

    (2012) A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B. PloS One 7:e32622.

    OpenUrlPubMed